Issue 61, 2020

Recent advances in the development of histone deacylase SIRT2 inhibitors

Abstract

Sirtuin 2 (SIRT2) is an important and special member of the atypical histone deacetylase Sirtuin (SIRT) family. Due to its extensive catalytic effects, SIRT2 can regulate autophagy, myelination, immunity, inflammation and other physiological processes. Recent evidence revealed that dysregulation of human SIRT2 activity is associated with the pathogenesis and prognosis of cancers, Parkinson's disease and other disorders; thus SIRT2 is a promising target for potential therapeutic intervention. This review presents a systematic summary of nine chemotypes of small-molecule SIRT2 inhibitors, particularly including the discovery and structural optimization strategies, which will be useful for future efforts to develop new inhibitors targeting SIRT2 and associated target proteins.

Graphical abstract: Recent advances in the development of histone deacylase SIRT2 inhibitors

Article information

Article type
Review Article
Submitted
20 Jul 2020
Accepted
05 Oct 2020
First published
09 Oct 2020
This article is Open Access
Creative Commons BY license

RSC Adv., 2020,10, 37382-37390

Recent advances in the development of histone deacylase SIRT2 inhibitors

W. Yang, W. Chen, H. Su, R. Li, C. Song, Z. Wang and L. Yang, RSC Adv., 2020, 10, 37382 DOI: 10.1039/D0RA06316A

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements